{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:22:18Z","timestamp":1791404538181,"version":"4.3.3"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRP"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Background: Vascular endothelial growth factor (VEGF) is one of the classic factors to\ntumor-induced angiogenesis in several types, including melanoma. Bevacizumab is a humanized\nmonoclonal antibody directed against VEGF.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title\/>\n<jats:p>\nObjective: To radiolabel Bevacizumab with 177-Lutetium as a potential radioimmunotherapy agent\nfor melanoma.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title\/>\n<jats:p>\nMethods: Bevacizumab was derivatized with DOTA-NHS-ester at 4 \u00baC for 18 h. DOTABevacizumab\nwas radiolabeled with 177LuCl3 (15 MBq\/mg) at 37 \u00baC for 1 h. The studies were performed\nin healthy and B16F1 tumor-bearing C57BL\/6J mice at 24 and 48 h (n = 5). Scinthigraphic\nimaging studies were performed at 24 h to determine the radiochemical stability, targeting specificity\nand pharmacokinetics of the 177Lutetium-labeled antibody.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title\/>\n<jats:p>\nResults: DOTA-Bevacizumab was efficiently labeled with 177LuCl3 at 37 \u00b0C. The in-vitro stability of\nlabeled product was optimal over 72 h. In-vivo biodistribution studies showed a high liver and tumor\nuptake of 177Lu-DOTA-Bevacizumab, with tumor-to-muscle ratios of 11.58 and 6.37 at 24 and 48 h\np.i. Scintigraphic imaging of melanoma tumor-bearing C57BL\/6J mice showed liver and a high tumor\nselective uptake of 177Lu-DOTA-Bevacizumab at 24 h.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title\/>\n<jats:p>\nConclusions: Our results support the potential role of 177Lu-DOTA-Bevacizumab as a novel radioimmunotherapy\nagent for melanoma. We hope that these novel molecular imaging agents will open\nthe path to new diagnostic and therapeutic strategies for Melanoma disease.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title\/>\n<jats:p\/>\n<\/jats:sec>","DOI":"10.2174\/1874471009666161010155246","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T04:41:32Z","timestamp":1478148092000},"page":"21-28","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma"],"prefix":"10.2174","volume":"10","author":[{"given":"Ximena","family":"Camacho","sequence":"first","affiliation":[{"name":"Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Rep\u00fablica, Mataojo 2055, 11400 Montevideo,Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Calzada","sequence":"additional","affiliation":[{"name":"Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Mataojo 2055, 11400 Montevideo,Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Mataojo 2055, 11400 Montevideo,Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alonso","sequence":"additional","affiliation":[{"name":"Centro de Medicina Nuclear, Hospital de Cl\u00ednicas ,Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Chammas","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Oncologia Experimental, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo N\u00ba 455- Cerqueira Cesar - CEP: 01246903 , Sao Paulo,Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa","family":"Riva","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Hematol\u00f3gica. Hospital de Cl\u00ednicas. Facultad de Medicina. Universidad de la Republica, Montevideo,Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Gambini","sequence":"additional","affiliation":[{"name":"Centro de Medicina Nuclear, Hospital de Cl\u00ednicas ,Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Cabral","sequence":"additional","affiliation":[{"name":"Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Rep\u00fablica, Mataojo 2055, 11400 Montevideo,Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874471009666161010155246","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/146214\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874471009666161010155246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T11:33:13Z","timestamp":1657279993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/146214\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874471009666161010155246","relation":{},"ISSN":["1874-4710"],"issn-type":[{"value":"1874-4710","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2016-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}